ProQR to Host R&D Day in New York on January 29
January 03 2019 - 7:00AM
ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research &
Development Day for investors on Tuesday, January 29 at 8:00 am ET
at the Lotte New York Palace Hotel in New York, NY.
The R&D day will feature presentations by internal ProQR and
external speakers on the progress of the ophthalmology pipeline,
including an update on the progress of sepofarsen (formerly named
QR-110) for LCA10 and QR-421a for Usher syndrome and discussion of
the next therapies to enter the clinic. Speakers will discuss state
of the art in research relevant to current and upcoming areas of
the company’s pipeline, including the role oligonucleotide
therapies will play in accelerating the translation of molecular
insights into approved therapies for areas of high unmet medical
need.
R&D Day Event Details
The event will be held on Tuesday, January 29, 2019 at the Lotte
New York Palace Hotel in New York City. Doors will open at 7:30 am
and will end around noon. Registration for the event can be
found at ProQR R&D Day Registration.
Webcast
The live and archived webcast of the presentation will be
accessible from the Investor Relations section of ProQR’s website
(www.proqr.com) under Events and Presentations. The archived
webcast will be available for 90 days following the presentation
date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the
creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis
10, Usher syndrome type 2 and dystrophic epidermolysis bullosa.
Based on our unique proprietary RNA repair platform technologies we
are growing our pipeline with patients and loved ones in mind.
*Since 2012*
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as "anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "look forward to", "may," "plan," "potential," "predict,"
"project," "should," "will," "would" and similar expressions,
including statements regarding the progress of our development and
plans for our product candidates. Forward-looking statements are
based on management's beliefs and assumptions and on information
available to management only as of the date of this press release.
Our actual results could differ materially from those anticipated
in these forward-looking statements for many reasons, including,
without limitation, the risks, uncertainties and other factors in
our filings made with the Securities and Exchange Commission,
including certain sections of our annual report filed on Form 20-F.
Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements,
even if new information becomes available in the future, except as
required by law.
ProQR Therapeutics N.V.Investor Contact:Lisa
HayesVice President of Investor Relations and Corporate
CommunicationsT: +1 202 360 4855ir@proqr.com
Media Contact:Sara ZelkovicLifeSci Public RelationsT: +1 646 876
4933Sara@lifescipublicrelations.com
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Apr 2023 to Apr 2024